LUNAPHORE-TECHNOLOGIES
13.5.2021 17:02:14 CEST | Business Wire | Press release
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the appointment of Matthias Weber, former President of Leica Biosystems, to its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005627/en/
Mr. Weber brings extensive experience in the cancer diagnostics and immunohistochemistry fields, marked by excellence in a range of diverse strategic roles including Product Management, R&D, Operations, Sales & Marketing, and most notably as President at Leica Biosystems, a position which he held between 2012 and 2019.
Mr. Weber commented: “I am delighted to join Lunaphore’s Board and to be part of a great team of innovators that will change the future of Immunohistochemistry (IHC) and Cancer Diagnostics”, and he added: “especially in the field of immuno-oncology, the Lunaphore high-plex staining technology offers researchers unique opportunities to simultaneously identify multiple markers while preserving the morphology of the tissue and cells.”
With this appointment, Lunaphore aims to strengthen its position in the field of spatial biology. Mr. Weber’s expert engagement will be instrumental in assisting the efforts to consolidate the company as a leading provider of innovative solutions for immuno-oncology research and tissue analysis.
Lunaphore’s Chairman of the Board, Joe Bernardo, said: “I am excited to have Matthias Weber, MD join our Board. Matthias is a great business leader with global experience at GE Healthcare and Danaher. The knowledge acquired during his 7 years at the helm of Leica Biosystems, a global leader in Anatomical Pathology and especially in Immunohistochemistry, will help us to fully exploit the company’s potential by supporting Lunaphore with the creation of a world class network of KOLs, providing guidance to achieve successful instrument launches into global markets and building strategic partnerships”.
About Mr. Weber
Matthias Weber is an international executive with more than 20 years of experience in the Medical Devices and Diagnostics industries. He is a Medical Doctor (MD; PhD) by training, and has professional experience in Cardiology, successively leading positions in Product Management, R&D, Operations and Sales & Marketing. Since 2004 global P&L responsibility with multiple global locations. From 2012 until 2019 he was the President of Leica Biosystems, a leading $1B Cancer Diagnostics company with extensive presence in the Immunohistochemistry (IHC) space.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company transforming the field of spatial biology in cancer research and tissue analysis through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of accelerating spatial biology and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005627/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Media Release: Allianz Beach Arena for the LA28 Olympic and Paralympic Games Joins the Allianz Family of Stadiums26.10.2026 15:37:00 CET | Press release
First Olympic and Paralympic venue in history to display the Allianz name and the eighth member of the Allianz Family of Stadiums.The nearly 15,000 seat temporary arena on the Long Beach waterfront will host Olympic Beach Volleyball and Paralympic Blind Football (Soccer).Allianz unveils its customized LA28 Games emblem, marking the start of its preparations for the LA28 Olympic and Paralympic Games. For the first time in Olympic and Paralympic history, a competition venue will carry the Allianz name. The Allianz Beach Arena in Long Beach, California, for the LA28 Olympic and Paralympic Games will become the newest member of the Allianz Family of Stadiums. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026919959/en/ Allianz's "custom A" emblem for LA28. From Horse Guards Parade in London to Copacabana Beach in Rio and the Eiffel Tower in Paris, Olympic Beach Volleyball has always found its home in iconic settings around th
Even Realities Brings Classic Tortoiseshell Design to Smart Glasses with New Even G2 Brown 226.10.2026 15:00:00 CET | Press release
The new brown colorway pairs traditional eyewear craftsmanship with display-first technology, alongside Even G2 Clip (Polarized) and Even G2 Chain Even Realities, the company behind camera-free, display-first smart glasses, today introduced Brown 2, a new tortoiseshell-inspired colorway for Even G2, alongside two accessories: Even G2 Clip (Polarized) and the Even G2 Chain. Designed to bring the warmth and character of traditional tortoiseshell eyewear to smart glasses, Brown 2 features a newly developed material that carries its layered pattern throughout the frame rather than applying it as a surface finish. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026502782/en/ Even G2 Chain. Photo Credit: Even Realities Each frame is individually shaped, pressed, tumbled, and polished for 20 hours, creating subtle variations that make every pair unique. Brown 2 is also the lightest Even G2 design to date, while retaining the came
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 202626.10.2026 14:45:00 CET | Press release
INCB161734 (KRAS G12D inhibitor) and INCA338901 (TGFβR2×PD-1 bispecific antibody) data reinforce ongoing and planned registrational trials, including DAWN-303 in pancreatic ductal adenocarcinoma (PDAC) and NEXERA-303 in colorectal cancer (CRC), respectivelyNew data evaluating INCB161734 in CRC highlight its clinical activity across KRAS G12D-mutated tumor types and support initiation of a Phase 3 study in second-line CRC planned for 2027INCB161734 and INCA33890 demonstrated manageable safety profiles in combination with standard-of-care (SoC) chemotherapiesNew collaborations with Bristol Myers Squibb and Synnovation in PDAC to evaluate INCB161734 in combination with navlimetostat, an MTA-cooperative PRMT5 inhibitor, and SNV1521, a PARP1 inhibitor, respectivelyThese results and additional updates will be presented at an analyst and investor event on Monday, October 26, 2026, from 7:30 – 9:00 p.m. CET (2:30 – 4:00 p.m. EDT) Incyte (Nasdaq:INCY) announced new results from its advancing on
Bending Spoons Completes the Acquisition of Miro26.10.2026 14:00:00 CET | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) has completed the previously announced acquisition of Miro, the visual collaboration platform used by more than 250,000 organizations to brainstorm, plan, and build together. “Miro has built a strong business around a product that makes complex collaborative work feel simple,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Miro’s versatility has made it useful across a broad range of industries and workflows, while creating a robust foundation for further expansion. We believe there’s significant potential to build on these strengths. We look forward to drawing on Bending Spoons’ technologies and expertise to make Miro even more useful to customers and support its continued growth.” “Teams depend on Miro for innovating, alignment, coordination, and decisioning, and that need is only growing,“ said Andrey Khusid, CEO and co-founder of Miro. “In Bending Spoons, Miro has an owner who invests for the long term and cares deeply about product quali
Dubai Culture Opens Registration for ISEA2026 Dubai26.10.2026 13:09:00 CET | Press release
Dubai Culture and Arts Authority (Dubai Culture) has opened registration for the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), taking place from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data and Identity’. The symposium will be the largest edition to date, bringing together artists, researchers, and innovators from around the world to explore the intersection of art, science, and technology and exchange perspectives on the future of contemporary creative practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026652826/en/ Dubai Culture Opens Registration for ISEA2026 Dubai (Graphic: AETOSWire) The event supports Dubai Culture’s efforts to advance the digital arts ecosystem, deliver on its Digital Arts Roadmap objectives, and empower local talent. It also reinforces Dubai’s position as a global cultural reference, a leader in innovation, a driver of the creative econo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom